Lando P A, Edgington T S
J Immunol. 1985 Nov;135(5):3587-95.
To analyze unique molecular differences between normal and neoplastic cells, we have examined host responses to tumor cells. The present study provides the first evidence for an innate rapid recognitive response of the lymphoid system to some syngeneic tumors. The lymphoid procoagulant (PCA) response, a T cell-instructed monocyte response that activates proteases of the coagulation cascade culminating in thrombin formation, is considered a component of classic delayed-type hypersensitivity responses. We have demonstrated that three syngeneic rat mammary carcinomas elicit this cellular response in vitro in lymphoid cells of the unimmunized rat. The response was rapid, reaching maximum within 6 hr. Analysis was compounded by the constitutive PCA activity of some tumors; however, the PCA product produced in the response to tumor challenge in vitro was newly biosynthesized and was of lymphoid cell origin, differing from the PCA of tumor cells. The lymphoid PCA response was prothrombinase-like and did not require vitamin K for biosynthesis, nor were other gamma-carboxylation-dependent extrinsic pathway proteases other than prothrombin required for thrombin generation. Both in vivo and in vitro derived mammary carcinoma cells elicited the response, whereas a fibrosarcoma and nontransformed syngeneic cells did not. Tumor shed substances, which were devoid of PCA and sedimentable only in part at 100,000 X G, induced this cellular response. The same stimuli shed from tumor cells did not directly elicit a PCA response from elicited peritoneal macrophages; however, in the presence of T lymphocytes a PCA response of these macrophages was produced. This study provides novel information to indicate that a T-enriched lymphocyte-dependent monocyte-macrophage response to some tumors, before effective in vivo immunization, may participate in initial local protease generation and fibrin deposition, both thought to play a significant role in the local pathobiology of tumors.
为了分析正常细胞与肿瘤细胞之间独特的分子差异,我们研究了宿主对肿瘤细胞的反应。本研究首次证明了淋巴系统对某些同基因肿瘤存在先天性快速识别反应。淋巴促凝剂(PCA)反应是一种T细胞介导的单核细胞反应,可激活凝血级联反应中的蛋白酶,最终形成凝血酶,被认为是经典迟发型超敏反应的一个组成部分。我们已经证明,三种同基因大鼠乳腺癌在体外可在未免疫大鼠的淋巴细胞中引发这种细胞反应。该反应迅速,在6小时内达到最大值。由于某些肿瘤具有组成性PCA活性,分析变得复杂;然而,体外对肿瘤攻击产生反应时产生的PCA产物是新生物合成的,且来源于淋巴细胞,与肿瘤细胞的PCA不同。淋巴PCA反应类似凝血酶原酶,生物合成不需要维生素K,除凝血酶原外,凝血酶生成也不需要其他γ-羧化依赖的外源性途径蛋白酶。体内和体外来源的乳腺癌细胞均可引发该反应,而纤维肉瘤和同基因未转化细胞则不能。肿瘤脱落物质缺乏PCA,仅部分可在100,000×G下沉淀,可诱导这种细胞反应。肿瘤细胞脱落的相同刺激物不会直接引发诱导的腹腔巨噬细胞的PCA反应;然而,在T淋巴细胞存在的情况下,这些巨噬细胞会产生PCA反应。本研究提供了新的信息,表明在有效的体内免疫之前,富含T细胞的淋巴细胞依赖性单核细胞-巨噬细胞对某些肿瘤的反应可能参与初始局部蛋白酶生成和纤维蛋白沉积,这两者都被认为在肿瘤局部病理生物学中起重要作用。